Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 01 12:51PM ET
16.65
Dollar change
-0.30
Percentage change
-1.77
%
IndexRUT P/E- EPS (ttm)-3.12 Insider Own21.97% Shs Outstand23.71M Perf Week19.96%
Market Cap396.44M Forward P/E- EPS next Y-3.66 Insider Trans95.79% Shs Float18.58M Perf Month66.00%
Income-74.07M PEG- EPS next Q-1.01 Inst Own82.14% Short Float1.79% Perf Quarter258.06%
Sales0.00M P/S- EPS this Y20.77% Inst Trans-0.45% Short Ratio2.87 Perf Half Y166.40%
Book/sh5.29 P/B3.15 EPS next Y-4.57% ROA-39.74% Short Interest0.33M Perf Year9.18%
Cash/sh5.44 P/C3.06 EPS next 5Y- ROE-46.47% 52W Range3.72 - 20.00 Perf YTD144.85%
Dividend Est.- P/FCF- EPS past 5Y- ROI-51.68% 52W High-16.75% Beta1.61
Dividend TTM- Quick Ratio6.35 Sales past 5Y0.00% Gross Margin- 52W Low347.58% ATR (14)1.24
Dividend Ex-Date- Current Ratio6.35 EPS Y/Y TTM85.35% Oper. Margin0.00% RSI (14)71.24 Volatility8.94% 11.01%
Employees45 Debt/Eq0.16 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price21.20
Option/ShortNo / Yes LT Debt/Eq0.14 EPS Q/Q-23.97% Payout- Rel Volume1.13 Prev Close16.95
Sales Surprise- EPS Surprise-10.86% Sales Q/Q- EarningsNov 08 BMO Avg Volume116.00K Price16.65
SMA2022.23% SMA5070.38% SMA200107.08% Trades Volume73,769 Change-1.77%
Date Action Analyst Rating Change Price Target Change
Dec-21-22Initiated H.C. Wainwright Buy $26
Feb-29-24 03:02AM
Feb-20-24 08:00AM
Feb-07-24 07:30AM
Jan-17-24 07:00AM
Jan-08-24 07:00AM
08:00AM Loading…
Dec-18-23 08:00AM
Nov-15-23 08:00AM
Nov-08-23 08:00AM
Oct-12-23 07:00AM
Sep-27-23 04:16PM
Sep-06-23 04:05PM
08:00AM
Sep-01-23 08:00AM
Aug-08-23 08:15AM
Jun-13-23 04:05PM
11:44AM Loading…
May-31-23 11:44AM
May-30-23 04:05PM
May-18-23 07:00AM
May-11-23 07:00AM
May-04-23 08:00AM
Apr-17-23 08:00AM
Apr-13-23 04:05PM
Mar-27-23 02:25AM
Mar-23-23 04:05PM
Mar-22-23 08:00AM
Mar-21-23 04:05PM
Mar-16-23 08:00AM
Mar-13-23 08:00AM
Feb-27-23 08:50AM
Feb-09-23 08:00AM
08:50AM Loading…
Jan-31-23 08:50AM
Jan-16-23 05:10AM
Jan-13-23 08:50AM
Dec-21-22 02:25PM
Dec-07-22 08:00AM
Dec-01-22 09:55AM
Nov-21-22 08:50AM
Nov-15-22 09:55AM
Nov-14-22 08:00AM
Nov-10-22 08:00AM
Nov-08-22 08:00AM
Oct-13-22 01:00PM
Sep-28-22 01:59PM
09:25AM
06:00AM
Sep-22-22 08:00AM
Sep-04-22 07:17AM
Aug-12-22 08:00AM
Aug-08-22 10:51AM
Jul-22-22 07:45AM
Jun-16-22 08:30AM
May-27-22 05:22PM
May-05-22 11:34PM
PepGen Inc. develops oligonucleotide therapies. It is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company was founded in March 26, 2018 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RA CAPITAL MANAGEMENT, L.P.DirectorFeb 09Buy10.642,557,59327,212,7909,179,273Feb 13 04:33 PM
McArthur James GPresident and CEONov 30Buy4.171,6947,0561,694Dec 05 07:34 AM
McArthur James GPresident and CEOJun 08Option Exercise2.712,3816,4532,381Jun 09 07:06 PM
McArthur James GPresident and CEOJun 08Sale16.042,38138,1880Jun 09 07:06 PM
McArthur James GPresident and CEOJun 07Option Exercise2.718,41922,8158,419Jun 08 05:23 PM
McArthur James GPresident and CEOJun 07Sale16.238,419136,6180Jun 08 05:23 PM
McArthur James GPresident and CEOJun 06Option Exercise2.7118,15049,18618,150Jun 08 05:23 PM
McArthur James GPresident and CEOJun 06Sale16.1818,150293,6600Jun 08 05:23 PM
McArthur James GPresident and CEOJun 05Option Exercise2.715001,355500Jun 06 04:19 PM
McArthur James GPresident and CEOJun 05Sale16.065008,0280Jun 06 04:19 PM
McArthur James GPresident and CEOJun 02Option Exercise2.711,8004,8781,800Jun 06 04:19 PM
McArthur James GPresident and CEOJun 02Sale16.041,80028,8630Jun 06 04:19 PM
Goyal JayaEVP, Res. & Preclin. Dev.Mar 24Option Exercise10.883924,265392Mar 28 07:36 PM
Goyal JayaEVP, Res. & Preclin. Dev.Mar 24Sale20.003927,8400Mar 28 07:36 PM